Core Viewpoint - Jin Hai Medical Technology (02225) experienced a significant stock price increase of over 41% in the afternoon trading session, with a cumulative rise exceeding 80% post-earnings announcement [1] Financial Performance - The company reported a revenue of SGD 14.529 million, representing a year-on-year decrease of 43.98% [1] - Shareholder losses amounted to SGD 10.253 million, which is a year-on-year increase of 69.67% [1] Capital Raising and Use of Proceeds - The company plans to issue 120 million new shares, which will represent approximately 2.27% of the enlarged share capital [1] - The net proceeds from this issuance are expected to be around HKD 161 million, intended for potential acquisitions in the healthcare sector, funding for research and development, and general working capital [1] Strategic Partnerships - On July 2, the company's wholly-owned subsidiary, Shanghai Jin Hai Medical Technology Co., Ltd., entered into a five-year cooperation framework agreement with Ningbo David Medical Instruments Co., Ltd. [1] - This agreement aims to collaborate on endoscope products in the international market, focusing on creating competitive high-end medical device solutions [1]
今海医疗科技午后涨超41% 绩后累涨超80% 此前配股筹资用于潜在并购及投资项目